Scagliotti et al. (2019) conducted a multicenter, randomized controlled, open-label, phase II study on erlotinib (150 mg QD) plus emibetuzumab (750 mg Q2W) as first-line treatment for EGFR-mutation-positive stage IV NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.